Susquehanna International Group
VKTX icon

Susquehanna International Group’s Viking Therapeutics VKTX Stock Holding History

Susquehanna International Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.1M Sell
956,500
-600,200
-39% -$19.3M ﹤0.01% 1704
2025
Q4 		$54.8M Sell
1,556,700
-216,000
-12% -$7.65M 0.01% 1285
2025
Q3 		$46.6M Sell
1,772,700
-72,600
-4% -$2.17M 0.01% 1397
2025
Q2 		$48.9M Buy
1,845,300
+111,300
+6% +$2.93M 0.01% 1190
2025
Q1 		$41.9M Buy
1,734,000
+222,400
+15% +$7.03M 0.01% 1134
2024
Q4 		$60.8M Buy
1,511,600
+191,200
+14% +$10.9M 0.01% 977
2024
Q3 		$83.6M Sell
1,320,400
-595,500
-31% -$34.9M 0.01% 744
2024
Q2 		$102M Sell
1,915,900
-882,100
-32% -$57.8M 0.02% 599
2024
Q1 		$229M Buy
2,798,000
+2,253,100
+413% +$100M 0.04% 375
2023
Q4 		$10.1M Buy
544,900
+133,500
+32% +$1.75M ﹤0.01% 2629
2023
Q3 		$4.55M Sell
411,400
-166,500
-29% -$2.38M ﹤0.01% 3698
2023
Q2 		$9.37M Buy
577,900
+230,300
+66% +$4.82M ﹤0.01% 2587
2023
Q1 		$5.79M Buy
347,600
+262,700
+309% +$2.71M ﹤0.01% 3236
2022
Q4 		$798K Buy
84,900
+20,700
+32% +$92.4K ﹤0.01% 6675
2022
Q3 		$175K Buy
64,200
+40,000
+165% +$131K ﹤0.01% 11032
2022
Q2 		$70K Sell
24,200
-28,000
-54% -$69.3K ﹤0.01% 11772
2022
Q1 		$157K Buy
52,200
+22,400
+75% +$80.4K ﹤0.01% 11516
2021
Q4 		$137K Sell
29,800
-40,400
-58% -$226K ﹤0.01% 11897
2021
Q3 		$441K Buy
70,200
+15,700
+29% +$97K ﹤0.01% 9711
2021
Q2 		$326K Sell
54,500
-48,200
-47% -$286K ﹤0.01% 10589
2021
Q1 		$650K Sell
102,700
-95,900
-48% -$675K ﹤0.01% 8858
2020
Q4 		$1.12M Buy
198,600
+69,600
+54% +$422K ﹤0.01% 6461
2020
Q3 		$751K Buy
129,000
+6,600
+5% +$45.4K ﹤0.01% 6804
2020
Q2 		$883K Sell
122,400
-40,600
-25% -$270K ﹤0.01% 6197
2020
Q1 		$763K Sell
163,000
-107,700
-40% -$662K ﹤0.01% 5996
2019
Q4 		$2.17M Sell
270,700
-12,800
-5% -$93.3K ﹤0.01% 4187
2019
Q3 		$1.95M Sell
283,500
-32,400
-10% -$241K ﹤0.01% 4245
2019
Q2 		$2.62M Sell
315,900
-213,500
-40% -$1.82M ﹤0.01% 3675
2019
Q1 		$5.26M Buy
529,400
+370,700
+234% +$3.1M ﹤0.01% 2391
2018
Q4 		$1.21M Sell
158,700
-189,800
-54% -$2.27M ﹤0.01% 4322
2018
Q3 		$6.07M Buy
348,500
+201,100
+136% +$2.39M ﹤0.01% 2448
2018
Q2 		$1.4M Buy
147,400
+121,100
+460% +$806K ﹤0.01% 4679
2018
Q1 		$115K Buy
+26,300
New +$145K ﹤0.01% 8645

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's VKTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, selling an estimated $23.1M and leaving 705,809 shares worth $23M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Susquehanna International Group first reported a position in VKTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $74.5M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Susquehanna International Group held 705,809 shares of Viking Therapeutics worth $23M as of Q1 2026.
  • Susquehanna International Group sold 718,022 Viking Therapeutics shares in Q1 2026, an estimated $23.1M.
  • Viking Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2060 holding.
  • Susquehanna International Group first reported a position in Viking Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • Susquehanna International Group's Viking Therapeutics position peaked at $74.5M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.